Ironically, if Biogen keeps withholding information to protect their share of the market and keep the investors happy they could be shooting themselves in the foot. Patients may not have a lot of power but they have some. If patients decide to go off Tysabri or refuse to begin it because of the lack of transparency then it could still wind up hurting Biogen and the investors. I think they made a poor call when it comes to disseminating information--they hoped us "passive" patients would just keep taking the drug if they stayed quiet. I think they also hoped the PML cases wouldn't be high enough to ultimately cause concern. But I think the line has been crossed. Bad policy and planning on their part. (not to mentione ethically questionable)